Diagnosis and treatment of myocardial fibrosis in hypertensive heart disease

Circulation Journal

Volumn 72, Issue SUPPL. A, 2008, Pages

  Díez, Javier ^a,b,c  

^a Centre for Applied Medical Research

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Collagen; Fibrosis; Hypertension; Hypertrophy

Indexed keywords

AMLODIPINE; ATENOLOL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FENOFIBRATE; FUROSEMIDE; GADOLINIUM; HYDROCHLOROTHIAZIDE; INDIUM 111; LISINOPRIL; LOSARTAN; TECHNETIUM 99M; TORASEMIDE;

ARTICLE; BIOCHEMISTRY; DIASTOLIC DYSFUNCTION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHIES; FIBROSIS; HUMANS; HYPERTENSION; MYOCARDIUM;

EID: 52949091463     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-07-1067     Document Type: Article

References (57)

1. Díez J. Hypertensive heart disease. In: Lip GYH, Hall JE, editors. Comprehensive hypertension. Philadelphia, PA: Mosby Elsevier; 2007; 621-631.
2. Díez J, González A, López B, Querejeta R. Mechanisms of disease: Pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005; 2: 209-216.
3. Díez J, López B, González A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001; 16: 328-335.
4. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-581.
5. Olivetti G, Melissari M, Balbi T, Quaini F, Cigola E, Sonnenblick EH, et al. Myocyte cellular hypertrophy is responsible for ventricular remodeling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994; 28: 1199-1208.
6. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-1041.
7. Ciulla M, Paliotti R, Hess DB, Tjahja E, Campbell SE, Magrini F, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657-664.
8. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220-225.
9. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
10. Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-1735.
11. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 2007; 9: 546-550.
12. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117: 568-575.
13. McLenachan JM, Dargie JH. Ventricular arrhythmias in hypertensive left ventricular hypertrophy: Relation to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990; 3: 735-740.
14. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: Relation to myocardial fibrosis. Circulation 2004; 110: 1263-1268.
15. Sugihara N, Genda A, Shimizu M, Suematu T, Kita Y, Horita Y, et al. Quantitation of myocardial fibrosis and its relation to function in essential hypertension and hypertrophic cardiomyopathy. Clin Cardiol 1988; 11: 771-778.
16. Ohsato K, Shimizu M, Sugihara M, Konishi K, Takeda R. Histopathological factors related to diastolic function in myocardial hypertrophy. Jpn Circ J 1992; 56: 325-333.
17. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-2517.
18. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothor Surg 2006; 30: 604-610.
19. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure: Treatment strategies. Heart Fail Rev 2008; 13: 367-375.
20. Tamirisa PK, Holland MR, Miller JG, Pérez JE. Ultrasonic tissue characterization: Review of an approach to assess hypertrophic myocardium. Echocardiography 2001; 7: 593-597.
21. Kerut EK, Given M, Giles TD. Review of methods for texture analysis of myocardium from echocardiographic images: A means of tissue characterization. Echocardiography 2003; 20: 727-736.
22. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58-64.
23. López B, González A, Querejeta R, Díez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23: 1445-1451.
24. López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859-867.
25. López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291.
26. Maceira AM, Barba J, Varo N, Beloqui O, Díez J. Ultrasonic back-scatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002; 39: 923-928.
27. Lin YH, Shiau YC, Yen RF, Lin LC, Wu CC, Ho YL, et al. The relation between myocardial cyclic variation of integrated backscatter and serum concentrations of procollagen propeptides in hypertensive patients. Ultrasound Med Biol 2004; 30: 885-891.
28. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension 2001; 38: 588-591.
29. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
30. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effect of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-2035.
31. Veeraveedu PT, Watanabe K, Ma M, Thandavarayana RA, Palaniyandi SS, Yamaguchi K, et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol 2008; 75: 649-659.
32. Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol 2008; 581: 121-131.
33. Tsutamoto T, Sakai H, Wada A, Ishikawa C, Ohno K, Fujii M, et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2004; 44: 2252 - 2253.
34. Uchida T, Yamanaga K, Nishikawa M, Ohtaki Y, Kido H, Watanabe M. Anti-aldosteronic effect of torasemide. Eur J Pharmacol 1991; 205: 145-150.
35. Shalitin N, Schlesinger H, Levy MJ, Kessler E, Kessler-Icekson G. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: Evidence for co-regulation with type I collagen. J Cell Biochem 2003; 90: 397-407.
36. Moon JC, Prasad SK. Cardiovascular magnetic resonance and the evaluation of heart failure. Curr Cardiol Rep 2005; 7: 39-44.
37. Vöhringer M, Mahrholdt H, Yilmaz A, Sechtem U. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz 2007; 32: 129-137.
38. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhyth-mogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol 2005; 45: 98-103.
39. Shirani J, Dilsizian V. Molecular imaging in heart failure. Curr Opin Biotechnol 2007; 18: 65-72.
40. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling, Circulation 2005; 112: 3157-3167.
41. Chen J, Tung CH, Allport J, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction, Circulation 2005; 111: 1800-1805.
42. González A, López B, Querejeta R, Díez J. Regulation of myocardial fibrillar collagen by angiotensin II: A role in hypertensive heart disease? J Mol Cell Cardiol 2002; 34: 1585-1593.
43. Díez J, Laviades C, Orbe J, Zalba G, López B, González A, et al. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens 2003; 21: 2085-2092.
44. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004; 22: 1007-1015.
45. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, et al. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004; 22: 593-603.
46. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Ytomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxy-corticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferators-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-1488.
47. Iglarz M, Touyz RM, Viel MC, Paradis P, Amiri F, Diep QN, et al. Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocortioid-dependent hypertension. Hypertension 2003; 42: 737-743.
48. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPARa activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36: 295-304.
49. Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I. Stimulation of peroxisome-proliferator-activated receptor α (PPARα) attenuates cardiac fibrosis and endothelin-I production in pressure-overloaded rat hearts. Clin Sci 2002; 103(Suppl 48): 284S-288S.
50. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664-668.
51. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C, et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Circulation 2004; 44: 471-477.
52. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: Implications in fibrosis. Exp Biol Med 2002; 227: 301-314.
53. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Circulation 2001; 104: 576-581.
54. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35: 953-960.
55. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodeling and glomeruli loss of spontaneously hypertensive rats. Clin Sci 2005; 108: 349-355.
56. Porter KE, Turner NA, O'Regan DJ, Balmforth AJ, Ball SG Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61: 745-755.
57. Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros JG, Insel PA. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci USA 2005; 102: 437-442.